Medtronic (NYSE:MDT) announced today that the extended study phase of its MiniMed 780G insulin pump system produced positive data. Fridley, Minnesota-based Medtronic presented new data from the study of MiniMed 780G with the no-calibration, non-adjunctive Guardian 4 sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona. Data demonstrated sustained improvements in […]
Diabetes
Data shows improved outcomes with DarioHealth’s chronic condition management platform
DarioHealth (Nasdaq:DRIO) today announced real-world study data on the impact of managing diabetes and weight on a single digital platform. New York-based DarioHealth presented the published retrospective, real-world study observing its digital therapeutics platform at the Advanced Technologies and Treatments for Diabetes (ATTD) Conference in Barcelona. Get the full story at our sister site, MassDevice.
Glooko adds former Eli Lilly exec to its board of directors
Diabetes management technology developer Glooko announced today that it appointed Alfonso “Chito” Zulueta to its board of directors. Zulueta joins Palo Alto, California-based Glooko’s board having spent more than 30 years with Eli Lilly and Company, serving as a senior executive across an array of global business and commercial units. According to a news release, […]
Abbott, Camdiab, Ypsomed forge partnership for automated insulin delivery
Abbott (NYSE:ABT) announced today that it partnered with CamDiab and Ypsomed (SWX:YPSN) to produce an integrated automated insulin delivery (AID) system. The companies announced the partnership at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, Spain. It seeks to develop and commercialize the integrated AID system with an initial focus centered around […]
Insulet announces positive study data for Omnipod 5 for type 1, type 2 diabetes
Insulet (Nasdaq:PODD) today unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes. Acton, Massachusetts-based Insulet presented results from studies as well as user experience data for both type 1 and type 2 diabetes at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, […]
Sweetch adds American Diabetes Association exec to its advisory board
Chronic condition therapeutic developer Sweetch announced today that Dr. Robert A. Gabbay has joined the company as an advisor. Gabbay currently serves as the chief scientific and medical officer at the American Diabetes Association, leading the organization’s efforts to drive discovery in diabetes research, care and prevention. He also serves as an associate professor of […]
EMA gives positive opinion on Novo Nordisk’s human insulin with flexible storage
Novo Nordisk (NYSE:NVO) announced that the European Medicines Agency (EMA) granted a positive opinion on a storage update for insulin. EMA’s positive opinion relates to a proposed update to the storage conditions of two human insulins: Actrapid (short-acting insulin) and Insulatard (intermediate-acting insulin). Bagsværd, Denmark-based Novo Nordisk said in a news release that the EMA’s […]
How Insulet created its next-gen Omnipod 5
Insulet (NSDQ:PODD) added to its portfolio of life-changing diabetes management technologies when its Omnipod 5 received FDA clearance in January. Omnipod 5 provides easier glucose management, with no multiple daily injections, no tubes and zero fingersticks. Paired with Dexcom’s G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery […]
Carbon Health launches new virtual diabetes management program
Carbon Health announced today that it launched its diabetes program through its full integration with Steady Health. San Francisco-based Carbon Health acquired Steady Health and its platform for using continuous glucose monitoring (CGM) to personalize diabetes care in June 2021. The platform aims to simplify diabetes management with CGM monitoring and logging that provides a […]
Dexcom announces availability of G6 for Tricare members as formulary pharmacy benefit
Dexcom (Nasdaq:DXCM) announced that its G6 continuous glucose monitoring (CGM) system will be available through Tricare. San Diego-based Dexcom’s CGM will be more easily available to military members, their families and retirees with diabetes as a Tricare brand-name formulary pharmacy benefit. According to a news release, effective mid-April 2022, members with diabetes will be eligible […]